Today: 14 July 2026
Full Truck Alliance (YMM) stock slides on JPMorgan downgrade as investors look to next earnings
14 January 2026
1 min read

Full Truck Alliance (YMM) stock slides on JPMorgan downgrade as investors look to next earnings

New York, Jan 14, 2026, 12:07 ET — Regular session

  • Full Truck Alliance shares fell about 3% in midday New York trading
  • JPMorgan cut the stock to Underweight and lowered its price target
  • Traders are watching for the next earnings update and any new catalysts

Full Truck Alliance Co. Ltd shares slid on Wednesday, extending recent weakness after JPMorgan cut its rating on the U.S.-listed Chinese freight platform. The stock was down about 2.8% at $9.81.

The downgrade matters now because the stock has been leaning on “what’s next” — investors want clearer signs that newer initiatives can lift growth and margins, not just hold the line. Without that, analyst calls can move the tape more than usual.

JPMorgan’s note took a blunt view on near-term triggers. It said the stock’s risk/reward “has shifted meaningfully” and flagged “limited near-term catalysts” with pressure still showing up in order growth, the analyst wrote. TipRanks

The bank downgraded Full Truck to Underweight from Neutral — an “underweight” call means the broker expects the stock to underperform its coverage universe — and cut its price target to $8 from $11, according to the note.

JPMorgan pointed to steps Full Truck started in the second quarter of 2025 to tighten platform governance and expand internationally, saying they have not yet translated into “sustainable growth or margin improvement.” It also cited ongoing regulatory and macro challenges weighing on the core business.

The move left Full Truck underperforming broader China-linked trading on U.S. screens. China internet and large-cap China ETFs were slightly lower in midday trade.

Full Truck operates a digital freight platform in China that matches shippers with truckers and also sells transaction and value-added services tied to freight moves.

But the setup cuts both ways. If regulatory pressures ease and the company shows better visibility on the new initiatives — especially if order growth stabilizes — the “no catalysts” argument gets harder to defend, and short-term positioning can flip fast.

For now, the company’s own investor calendar is bare. Its IR site showed no upcoming events listed.

Traders will be watching for the next results date and any guidance around growth and margins, with Nasdaq’s earnings page estimating a report around March 4.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • BioCryst (BCRX) Jumps; Analysts Eye 118% Upside on Stock
    July 14, 2026, 11:31 AM EDT. BioCryst Pharmaceuticals (BCRX) shares moved up 9.4% to $9.91. Wall Street's mean price target is $21.60, pointing to a possible 118% gain. Ten analysts set targets from $14.00, a 41.3% increase, up to $32.00, a 223% jump. The $7.35 standard deviation shows some split among analysts. Forecasts call for stronger earnings revisions, a sign that can often lift a stock. But research finds these targets might be too optimistic and could confuse investors, since conflicts of interest sometimes exist. Closer target ranges generally mean more agreement, but that doesn't guarantee the shares will follow. Price targets are just one thing for investors to weigh.
Groww Q3 FY26 results: Why the stock jumped even as profit fell 28%
Previous Story

Groww Q3 FY26 results: Why the stock jumped even as profit fell 28%

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Next Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Go toTop